18F-Fluciclovine PET/CT in the Assessment of Pancreatic Transplants
Status:
Enrolling by invitation
Trial end date:
2022-08-31
Target enrollment:
Participant gender:
Summary
Hypothesis 1: 18F-Fluciclovine PET/CT can correctly and easily identify the pancreatic
allograft and determine its viability
Aim 1: Assess whether 18F-Fluciclovine can identify the pancreatic allograft accurately and
assess its viability and visibility
Hypothesis 2: 18F-Fluciclovine PET/CT uptake in the pancreas (SUV) is related to total
pancreatic function and therefore can indicate whether the pancreatic allograft is at risk of
rejection
Aim 2: Assess whether 18F-Fluciclovine uptake in the pancreas can be a surrogate for
pancreatic function